New hope is on the horizon in the fight against cancer. At this year’s American Society of Clinical Oncology (ASCO) annual ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B ...

Redwire Corporation (NYSE: RDW), a leader in space infrastructure for the next generation space economy, announced today that ...

Recent advances in cancer research have underscored the critical role of myeloid cells in shaping tumor microenvironments ...

MedtechWOMEN today announced the theme of its upcoming MedtechVISION 2025 Annual Conference, "Revolution not Evolution: Medtech’s Next Chapter", signaling a bold call to action—urging the medtech ...

Agenus announced it signed a partnership agreement with Zydus Lifesciences to expand patient access to Botensilimab and ...

BioNTech SE and BMS have partnered for the global co-development and co-commercialization of BNT327 across numerous solid ...

Agenus, which has been going through a reorganization after the FDA put the brakes on the biotech's regulatory plan for its ...

BMY strikes a billion-dollar deal with BNTX to co-develop BNT327, a bispecific antibody targeting PD-L1 and VEGF-A in solid ...

BioNTech’s BNT327 is being evaluated in multiple clinical trials, including phase 3 studies in first-line lung cancer ...

Investing.com -- Agenus Inc . (NASDAQ: AGEN) stock soared 30% following the announcement of a strategic collaboration with Zydus Lifesciences (NSE: ZYDU ), which includes a $141 million deal to ...